Skip to main content
SpringerLink
Log in

Studien — Einfluss auf die aktuelle und zukünftige Therapiequalität beim Ovarialkarzinom

  • Chapter
Management des Ovarialkarzinoms

Part of the book series: Onkologie aktuell ((ONKAKTUELL))

  • 1315 Accesses

Auszug

Die ungünstige Prognose insbesondere des fortgeschrittenen Ovarialkarzinoms trotz therapeutischer Standardisierung und Entwicklungen der operativen und systemischen Therapie erfordert weitere forschende Aktivitäten. Nationale und internationale Kooperationen wurden in den letzten Jahren mit dem Ziel aufgebaut, klinische Studien zu initiieren, in angemessenen Zeiträumen die Rekrutierung von Patientinnen zu komplettieren und so in aktuellen Zeitfenstern relevante Ergebnisse zu erzielen, die Einfluss auf die Fortentwicklung von Therapiestandards nehmen können, sei es, diese zu bestätigen oder zu ändern. Außerdem gibt es deutliche Hinweise, dass an klinischen Studien teilnehmende Zentren zum Nutzen der Patientinnen bestehende Therapie empfehlungen stringenter umsetzen und so zur bestmöglichen Therapiequalität beitragen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Bois, A. du et al. (2003) A randomized clinical trial of cisplatin/paditaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 (17), 1320–1329

    PubMed  Google Scholar 

  • Bois, A. du et al. (2005a) Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer 15 (2), 183–191

    Article  PubMed  Google Scholar 

  • Bois, A. du et al. (2005b) Impact of center characteristics on outcome in ovarian cancer in Germany. Zentralbl Gynakol 127 (1), 18–30

    Article  PubMed  Google Scholar 

  • GCIG (2006) CA 125 definitions agreed by GCIG November 2005. Verfügbar unter http://ctep.cancer.gov/resources/gcig/respdef_nov2005.doc[25.9.2008]

    Google Scholar 

  • Harter, P. et al. (2005) Non-enrolment of ovarian cancer patients in clinical trials: reasons and background. Ann Oncol 16 (11), 1801–1805

    Article  PubMed  CAS  Google Scholar 

  • Markman, M. et al. (2006) Influence of tumor type, disease status, and patient age on self-reported interest regarding participation in cancer clinical trials. Cancer 107 (4), 849–853

    Article  PubMed  Google Scholar 

  • Ozols, R.F. et al. (2003) Phase III trial of carboplatin and paditaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (17), 3194–3200

    Article  PubMed  CAS  Google Scholar 

  • Parmar, M.K. et al. (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (9375), 2099–2106

    Article  PubMed  CAS  Google Scholar 

  • Pfisterer, J. et al. (2006a) Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98 (15), 1036–1045

    Article  PubMed  CAS  Google Scholar 

  • Pfisterer, J. et al. (2006b) The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 17 (10), 1568–1577

    Article  PubMed  CAS  Google Scholar 

  • Ross, S. et al. (1999) Barriers to participation in randomised controlled trials: a systematic review. J Clin Epidemiol 52 (12), 1143–1156

    Article  PubMed  CAS  Google Scholar 

  • Rustin, G.J. (2003) Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21 (10 Suppl), 187–193.

    Article  Google Scholar 

  • Therasse, P. et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (3), 205–216

    Article  PubMed  CAS  Google Scholar 

  • Wagner, U. et al. (2006) Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy-A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol 105 (1), 132–137

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie, Universitätsklinikum Gießen und Marburg GmbH, Baldingerstraße 1, 35043, Marburg

    Dr. med. K. H. Baumann, H. B. Naujok & Prof. Dr. med. U. Wagner

Authors
  1. Dr. med. K. H. Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. B. Naujok
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. U. Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Medizin Verlag Heidelberg

About this chapter

Cite this chapter

Baumann, K.H., Naujok, H.B., Wagner, U. (2009). Studien — Einfluss auf die aktuelle und zukünftige Therapiequalität beim Ovarialkarzinom. In: Management des Ovarialkarzinoms. Onkologie aktuell. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68857-0_23

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-68857-0_23

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-41987-7

  • Online ISBN: 978-3-540-68857-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation